[The combined chemotherapy with vincristine, prospidin, bleomycin and cyclophosphane of epidermoid lung cancer].
The effectiveness of combination chemotherapy with vincristine, prospidin, bleomycin, cyclophosphamide and prednisolone (VPBCP regimen) was studied in 71 patients with morphologically verified locally advanced and inoperable epidermoid lung cancer. A more than 50% regression of tumor was registered in 32.4% with 4.2% showing complete response. Tumor shrank by 25-50% in 15.5% but failed to respond in 29.6%. Toxicity proved low. A direct correlation--the more apparent regression, the longer remission and, correspondingly, longer survival--was established between prognosis and response.
L A
LA
Dudareva
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000401:mortality; D003520:Cyclophosphamide / Q000008:administration & dosage; D004341:Drug Evaluation; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000401:mortality; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D011239:Prednisolone / Q000008:administration & dosage; D011447:Prospidium / Q000008:administration & dosage; D013997:Time Factors; D014750:Vincristine / Q000008:administration & dosage
D001761:Bleomycin; D014750:Vincristine; D011447:Prospidium; D003520:Cyclophosphamide; D011239:Prednisolone
Kombinirovannaia khimioterapiia vinkristinom, prospidinom, bleomitsinom i tsiklofosfanom épidermoidnogo raka legkogo.